Eosinophilic esophagitis (EOE) was first characterized as a disease state in the 1990s as a chronic inflammatory condition of the esophagus that results from an immune response to food allergens or aeroallergens. Dysphagia and food impaction are common symptoms of untreated EOE, which may be accompanied by histologic changes such as elevated inflammatory markers as well as esophageal strictures. Untreated persistent symptoms may be associated with negative impacts on mental health, such as anxiety and depression. Up to one-third of adults with EOE have a comorbid psychiatric diagnosis.
Because no medications are currently approved for treatment, management of EOE includes dietary and behavioral interventions as well as the off-label use of certain medications. However, there are several pipeline medications that are being investigated for the treatment of EOE. In this webinar, presenters will provide an overview of EOE for managed care professionals, discuss current treatment recommendations, and explore how emerging therapies may impact the management of this disease state.
At the completion of this knowledge-based activity, participants should be able to:
- Describe the prevalence and pathophysiology of eosinophilic esophagitis (EOE).
- Summarize current treatment recommendations for EOE.
- Describe EOE treatments in the pipeline and their potential role in the overall management of EOE.
- Review the financial consideration for the management of EOE.
Brian A. Hemstreet, PharmD, FCCP, BCPS
Associate Dean for Student Affairs and Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Patrick D. Meek, PharmD, MSPH
Associate Professor of Pharmacy
Albany College of Pharmacy and Health Sciences
Schedule of Educational Activity:
This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE UAN: 0233-0000-21-033-H01-P • Activity Type: Knowledge-Based
Contact Hours: 1
Release Date: August 26, 2021 • Expiration Date: December 31, 2022
Activity Fee: Free for Members and Non-Members
Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2021 Virtual.CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.
To receive credit for an online activity you must:
- Review the full content of the activity.
- Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
- Complete a specific activity evaluation.
This educational activity is supported by an unrestricted educational grant from Takeda Pharmaceuticals U.S.A., Inc..
As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.
System Technical Requirements/Viewing Requirements:
System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-21-033-H01-P||1 Contact Hour||August 26, 2021 - December 31, 2022|